Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jian-Ping Zhang & Anil K Malhotra. (2013) Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opinion on Drug Metabolism & Toxicology 9:2, pages 183-191.
Read now
Read now
John M. Kane & Christoph U. Correll. (2010) Pharmacologic treatment of schizophrenia. Dialogues in Clinical Neuroscience 12:3, pages 345-357.
Read now
Read now
Ramón Cacabelos. (2009) Pharmacogenomics and therapeutic strategies for dementia. Expert Review of Molecular Diagnostics 9:6, pages 567-611.
Read now
Read now
Articles from other publishers (34)
Nurul Ain Khoruddin, Wai Feng Lim, Lay Kek Teh, Mohd Nur Fakhruzzaman Noorizhab, Farida Zuraina Mohd Yusof & Mohd Zaki Salleh. (2022) Toward precision nutrition: A cross‐sectional study on the genetic risks of nutrients deficiencies and eating behaviors among the Orang Asli and Malays. Precision Medical Sciences.
Crossref
Crossref
Katarzyna Ochenkowska, Aveeva Herold & Éric Samarut. (2022) Zebrafish Is a Powerful Tool for Precision Medicine Approaches to Neurological Disorders. Frontiers in Molecular Neuroscience 15.
Crossref
Crossref
Takashi Tsuboi, Hirohisa Watanabe, Masahisa Katsuno & Gen Sobue. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
3243
3252
.
Gabriella Di Girolamo Martins, Veronica Vidotto Caricati, Beatriz Cortese Barbugli, Caroline Matilde da Silva Ribeiro, Fernanda Beatriz Hodar Lobato, Adriana Scatena, Renata Thurler Lessa, Denise De Micheli & André Luiz Monezi Andrade. 2021. Drugs and Human Behavior. Drugs and Human Behavior
459
468
.
Tatiyana Mandal, Laxminarayana Kurady Bairy & Podila Satya Venkata Narasimha Sharma. (2020) Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population. European Journal of Clinical Pharmacology 76:6, pages 807-814.
Crossref
Crossref
Jessica L. Bourdon, Rachel A. Davies & Elizabeth C. Long. (2020) Four Actionable Bottlenecks and Potential Solutions to Translating Psychiatric Genetics Research: An Expert Review. Public Health Genomics 23:5-6, pages 171-183.
Crossref
Crossref
Takashi Tsuboi, Hirohisa Watanabe, Masahisa Katsuno & Gen Sobue. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
10
.
Tomislav Bozek, Antonela Blazekovic, Matea Nikolac Perkovic, Kristina Gotovac Jercic, Aleksandra Sustar, Lea Smircic-Duvnjak, Tiago F. Outeiro, Nela Pivac & Fran Borovecki. (2017) The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 9:1.
Crossref
Crossref
Kristi Pettai, Lili Milani, Anu Tammiste, Urmo Võsa, Raivo Kolde, Triin Eller, David Nutt, Andres Metspalu & Eduard Maron. (2016) Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. European Neuropsychopharmacology 26:9, pages 1475-1483.
Crossref
Crossref
S M Bahr, B C Tyler, N Wooldridge, B D Butcher, T L Burns, L M Teesch, C L Oltman, M A Azcarate-Peril, J R Kirby & C A Calarge. (2015) Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Translational Psychiatry 5:10, pages e652-e652.
Crossref
Crossref
Ramón Cacabelos, Clara Torrellas, Pablo Cacabelos, María J. Villanueva, Sergio Piñeiro & Cristina Solveira. 2015. Preventive and Predictive Genetics: Towards Personalised Medicine. Preventive and Predictive Genetics: Towards Personalised Medicine
173
240
.
J Kambeitz, M Romanos & U Ettinger. (2013) Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD. The Pharmacogenomics Journal 14:1, pages 77-84.
Crossref
Crossref
Britt I. Drögemöller, Galen E.B. Wright, Dana J.H. Niehaus, Robin Emsley & Louise Warnich. (2013) Next-generation sequencing of pharmacogenes. Pharmacogenetics and Genomics 23:12, pages 666-674.
Crossref
Crossref
R. De Vecchis, C. Esposito & C. Ariano. (2013) Cabergoline use and risk of fibrosis and insufficiency of cardiac valvesCabergolingabe und Risiko einer Fibrose mit Herzklappeninsuffizienz. Herz 38:8, pages 868-880.
Crossref
Crossref
Ramón Cacabelos, Pablo Cacabelos & Gjumrakch Aliev. (2013) Genomics of schizophrenia and pharmacogenomics of antipsychotic drugs. Open Journal of Psychiatry 03:01, pages 46-139.
Crossref
Crossref
Firoza Mamdani, Maureen V. Martin, Todd Lencz, Brandi Rollins, Delbert G. Robinson, Emily A. Moon, Anil K. Malhotra & Marquis P. Vawter. (2013) Coding and Noncoding Gene Expression Biomarkers in Mood Disorders and Schizophrenia. Disease Markers 35, pages 11-21.
Crossref
Crossref
Ramón Cacabelos. (2012) Pharmacogenomics of Central Nervous System (CNS) Drugs. Drug Development Research 73:8, pages 461-476.
Crossref
Crossref
A K Malhotra, J-P Zhang & T Lencz. (2011) Pharmacogenetics in psychiatry: translating research into clinical practice. Molecular Psychiatry 17:8, pages 760-769.
Crossref
Crossref
Aiden Corvin & Michael Gill. 2012. Core Psychiatry. Core Psychiatry
35
53
.
Kenneth Blum, Thomas J. H. Chen, John Bailey, Abdalla Bowirrat, John Femino, Amanda L. C. Chen, Thomas Simpatico, Siobhan Morse, John Giordano, Uma Damle, Mallory Kerner, Eric R. Braverman, Frank Fornari, B. William Downs, Cynthia Rector, Debmayla Barh & Marlene Oscar-Berman. (2011) Can the Chronic Administration of the Combination of Buprenorphine and Naloxone Block Dopaminergic Activity Causing Anti-reward and Relapse Potential?. Molecular Neurobiology 44:3, pages 250-268.
Crossref
Crossref
Ramón Cacabelos & Rocío Martínez-Bouza. (2011) Genomics and Pharmacogenomics of Schizophrenia. CNS Neuroscience & Therapeutics 17:5, pages 541-565.
Crossref
Crossref
Qiyong Gong, Qizhu Wu, Cristina Scarpazza, Su Lui, Zhiyun Jia, Andre Marquand, Xiaoqi Huang, Philip McGuire & Andrea Mechelli. (2011) Prognostic prediction of therapeutic response in depression using high-field MR imaging. NeuroImage 55:4, pages 1497-1503.
Crossref
Crossref
Ramón Cacabelos, Ryota Hashimoto & Masatoshi Takeda. (2011) Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry and Clinical Neurosciences 65:1, pages 3-19.
Crossref
Crossref
Fabio Panariello, Vincenzo De Luca & Andrea de Bartolomeis. (2011) Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies. Schizophrenia Research and Treatment 2011, pages 1-16.
Crossref
Crossref
John S. March. (2011) Looking to the future of research in pediatric anxiety disorders. Depression and Anxiety 28:1, pages 88-98.
Crossref
Crossref
Ramón Cacabelos, Lucía Fernández-Novoa, Rocío Martínez-Bouza, Adam McKay, Juan C. Carril, Valter Lombardi, Lola Corzo, Iván Carrera, Iván Tellado, Laura Nebril, Margarita Alcaraz, Susana Rodríguez, Ángela Casas, Verónica Couceiro & Antón Álvarez. (2010) Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. Pharmaceuticals 3:10, pages 3040-3100.
Crossref
Crossref
K. G. Claw, R. Y. Tito, A. C. Stone & B. C. Verrelli. (2010) Haplotype Structure and Divergence at Human and Chimpanzee Serotonin Transporter and Receptor Genes: Implications for Behavioral Disorder Association Analyses. Molecular Biology and Evolution 27:7, pages 1518-1529.
Crossref
Crossref
S Le Hellard, T W Mühleisen, S Djurovic, J Fernø, Z Ouriaghi, M Mattheisen, C Vasilescu, M B Raeder, T Hansen, J Strohmaier, A Georgi, F F Brockschmidt, I Melle, I Nenadic, H Sauer, M Rietschel, M M Nöthen, T Werge, O A Andreassen, S Cichon & V M Steen. (2008) Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Molecular Psychiatry 15:5, pages 463-472.
Crossref
Crossref
S. Gentile. (2009) Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obesity Reviews 10:5, pages 527-542.
Crossref
Crossref
Sofia I. I. Kring, Thomas Werge, Claus Holst, Søren Toubro, Arne Astrup, Torben Hansen, Oluf Pedersen & Thorkild I. A. Sørensen. (2009) Polymorphisms of Serotonin Receptor 2A and 2C Genes and COMT in Relation to Obesity and Type 2 Diabetes. PLoS ONE 4:8, pages e6696.
Crossref
Crossref
Eduard Maron, Anu Tammiste, Kristi Kallassalu, Triin Eller, Veiko Vasar, David J. Nutt & Andres Metspalu. (2009) Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European Neuropsychopharmacology 19:6, pages 451-456.
Crossref
Crossref
Charles E Dean. (2009) Personalized Medicine: Boon or Budget-Buster?. Annals of Pharmacotherapy 43:5, pages 958-962.
Crossref
Crossref
Ramón Cacabelos. 2009. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes
3
63
.
Kenneth Blum, Amanda LihChuan Chen, Thomas JH Chen, Eric R Braverman, Jeffrey Reinking, Seth H Blum, Kimberly Cassel, Bernard W Downs, Roger L Waite, Lonna Williams, Thomas J Prihoda, Mallory M Kerner, Tomas Palomo, David E Comings, Howard Tung, Patrick Rhoades & Marlene Oscar-Berman. (2008) Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theoretical Biology and Medical Modelling 5:1.
Crossref
Crossref